ABCL — AbCellera Biologics Income Statement
0.000.00%
Last trade - 00:00- $1.02bn
- $488.22m
- $75.13m
Annual income statement for AbCellera Biologics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 375 | 485 | 38 | 28.8 | 75.1 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 171 | 269 | 275 | 344 | 292 |
| Operating Profit | 204 | 217 | -237 | -315 | -217 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 219 | 239 | -174 | -200 | -178 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 153 | 159 | -146 | -163 | -146 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 153 | 159 | -146 | -163 | -146 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 153 | 159 | -146 | -163 | -146 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.482 | 0.504 | -0.499 | -0.412 | -0.49 |